Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Biovica International AB is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active filing represents the company's current focus for patent protection in the pharmaceutical sector and reflects a targeted technical interest.
The prosecution is centralized, involving a distinct examiner and 1 distinct art unit. This indicates that the company's technology is being reviewed by a single specialist within a specific administrative division of the patent office, allowing for a direct and focused examination process.
SHELTON, SYNPHANE LA'SHAWN is the busiest examiner for the portfolio, currently responsible for 1 pending office action. As the only examiner currently reviewing the company's work, their individual perspective on Biotechnology & Pharmaceuticals will be the primary factor in the outcome of this pending matter. Practitioners should prioritize addressing the specific concerns raised by this examiner to secure the pending claims.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHELTON, SYNPHANE LA'SHAWN | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18859447 | THYMIDINE KINASE AS A MARKER FOR IMMUNE CHECKPOINT INHIBITOR EFFICACY | SHELTON, SYNPHANE LA'SHAWN | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859447 | THYMIDINE KINASE AS A MARKER FOR IMMUNE CHECKPOINT INHIBITOR EFFICACY | SHELTON, SYNPHANE LA'SHAWN | 1652 | §103§112 | Non-Final OA | — | Pending | Oct 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiovica International AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Synphane La'Shawn Shelton has the most, with 1 of Biovica International AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
